Protagonist Therapeutics presented the one‑year Phase 3 results for its oral IL‑23 receptor antagonist ICOTYDE (icotrokinra) at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The data, derived from the ICONIC‑ADVANCE 1 and 2 and ICONIC‑LEAD studies, demonstrate sustained skin clearance and a favorable safety profile in patients with moderate‑to‑severe plaque psoriasis.
The FDA approved ICOTYDE on March 18, 2026, unlocking a $50 million milestone payment for Protagonist. The company is also eligible for tiered royalties of 6‑10 % on global net sales and up to $580 million in future milestone payments, validating the commercial potential of its peptide‑engineering platform.
Protagonist reported $646 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing a runway through at least 2028. License and collaboration revenue fell sharply in 2025 versus 2024, and the company posted a net loss for the full year 2025. The milestone payment and future royalties will help offset operating costs and support the upcoming launch of ICOTYDE in the United States and internationally.
ICOTYDE’s oral administration differentiates it from injectable biologics and could expand its addressable market. Competitors include Sotyktu (deucravacitinib) and other biologics such as TNF inhibitors. The one‑year data strengthen ICOTYDE’s case for payer coverage and support premium pricing, positioning it as a first‑in‑class oral IL‑23R peptide.
CEO Dinesh V. Patel said, "The one‑year Phase 3 results presented at AAD reinforce our belief that ICOTYDE... has the potential to meaningfully expand treatment options for people living with moderate‑to‑severe plaque psoriasis." The presentation will support the upcoming launch and accelerate revenue generation.
Protagonist also has other pipeline assets, including rusfertide for polycythemia vera and PN‑881, an oral IL‑17 peptide antagonist, and is exploring additional inflammatory indications. Collaboration with Johnson & Johnson (Janssen Biotech) will drive commercialization of ICOTYDE and other products.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.